Business & Industry

BeOne Medicines has entered into a high-value agreement with Huahui Health, committing $20 million upfront to secure an exclusive option for a preclinical trispecific antibody candidate developed by the Chinese biotech firm. The asset, identified as HH160, targets PD-1,...

The U.S. Food and Drug Administration has unveiled a new regulatory initiative to enable real-time clinical trials, marking a structural shift in how drug development data is reviewed. The program, already supported by AstraZeneca and Amgen, introduces a model...

Chiesi Group has entered into a definitive agreement to acquire KalVista Pharmaceuticals, marking a significant step in strengthening its rare disease portfolio. Announced on 29 April 2026, the transaction will see Chiesi acquire all outstanding shares of KalVista for...

In a reversal of its earlier stance, AstraZeneca has confirmed a £300m commitment to the UK, marking a renewed push into domestic operations after previously halting major projects. The announcement, delivered in Parliament by Keir Starmer, signals a shift...

Teva Pharmaceuticals has entered into a definitive agreement to acquire Emalex Biosciences, strengthening its neuroscience pipeline through the addition of ecopipam, a late-stage investigational treatment for pediatric Tourette syndrome. The move reinforces the company’s strategic shift toward innovation-led expansion,...

Sun Pharmaceutical Industries has agreed to acquire Organon in a transaction valued at $11.75 billion, creating what the company described as the largest Biopharma Deal recorded in 2026. The agreement brings together two businesses that each generated $6.2 billion...

The US Food and Drug Administration has awarded three additional Commissioner's National Priority Vouchers under its accelerated regulatory framework, targeting companies developing psychedelic-based therapies. The move follows President Donald Trump’s April 18 executive order aimed at advancing mental health...